The KRAS Mutation Problem KRAS is one of the most frequently mutated oncogenes in lung adenocarcinoma, historically considered undruggable. The recent approval of sotorasib (targeting KRASG12C) and adagrasib has opened new treatment avenues, but not all patients respond equally. Understanding the molecular consequences of KRAS inhibition - including effects on RNA processing - is critical for predicting and improving therapy outcomes.
Alternative Splicing as a Cancer Mechanism Alternative splicing (AS) is the process by which a single gene can produce multiple protein variants by selectively including or excluding exon sequences. In cancer, aberrant splicing creates protein isoforms that may support tumor survival or drug resistance. Microexons - tiny exon sequences of 3 to 27 nucleotides - are particularly impactful because small sequence changes can profoundly alter protein function.
The RPS24 Gene and Its Microexons RPS24 encodes ribosomal protein S24, a component of the 40S ribosomal subunit that governs mRNA translation efficiency and selectivity. This study identified three distinct microexons within RPS24 - measuring 3, 18, and 22 base pairs respectively - making it an unusually complex splicing target among ribosomal genes.
Study Purpose The investigators used high-resolution fragment analysis techniques to detect and quantify specific RPS24 microexon isoforms in lung adenocarcinoma cell lines before and after treatment with KRAS inhibitors. The goal was to determine whether KRAS pathway inhibition alters RPS24 splicing patterns in a way that could serve as a pharmacodynamic biomarker.
The Fragment Analysis Technique Standard RT-PCR cannot resolve microexon isoforms differing by only 3-22 nucleotides. Fragment analysis - a capillary electrophoresis method that separates PCR products by size with single-base resolution - was employed to distinguish and quantify each RPS24 microexon isoform separately. Fluorescently labeled primers allowed precise measurement of isoform abundance ratios.
Cell Line Models Multiple lung adenocarcinoma cell lines harboring KRASG12C and other KRAS mutations were treated with sotorasib and adagrasib at clinically relevant concentrations. A key advantage of this approach is that cell lines provide a controlled system where the effect of KRAS inhibition can be isolated from confounding clinical variables.
Quantification of Isoform Ratios Rather than simply detecting the presence of isoforms, the study quantified the relative abundance of each RPS24 splice variant as a fraction of total RPS24 mRNA. This semi-quantitative approach allows tracking of splicing dynamics over time and across drug concentrations, providing a pharmacodynamic readout linked to KRAS pathway inhibition.
Validation Across Multiple Conditions Experiments were performed across multiple KRAS mutant cell lines, different time points after drug treatment, and dose-response conditions to ensure that the observed splicing changes were reproducible and KRAS-specific rather than non-specific cellular stress responses.
Baseline Isoform Distribution Under untreated conditions, RPS24 mRNA in lung adenocarcinoma cells predominantly uses the 18 bp and 22 bp microexon-containing isoforms. The 3 bp microexon isoform (ex4:3bp) was expressed at comparatively low levels, suggesting that active KRAS signaling suppresses or deprioritizes this specific splice variant.
Upregulation After KRAS Inhibition Following treatment with sotorasib or adagrasib, the ex4:3bp isoform showed consistent and significant upregulation across multiple KRASG12C cell lines. This change occurred within 24-48 hours of treatment and was dose-dependent, indicating that the splicing shift is a direct pharmacodynamic consequence of KRAS pathway suppression rather than a secondary adaptive response.
Isoform-Specific Functional Implications The three microexon isoforms of RPS24 encode ribosomal proteins with subtly different structures in a functionally critical region. Differences in this region may alter ribosome composition and, consequently, translational selectivity - meaning that the drug-induced splicing shift could change which mRNAs are preferentially translated, potentially affecting cellular adaptation to KRAS inhibition.
Consistency Across Multiple Lines The upregulation of the ex4:3bp isoform was observed in cell lines with different genetic backgrounds and different KRAS mutations beyond G12C, suggesting that this splicing response reflects a broader effect of attenuating KRAS-downstream signaling rather than a mutation-specific event.
What Makes a Good Pharmacodynamic Biomarker An ideal pharmacodynamic biomarker changes reliably in response to target engagement, can be measured non-invasively or with minimal invasiveness, and provides early indication of whether therapy is achieving its intended molecular effect. The ex4:3bp isoform ratio satisfies the first criterion and is potentially measurable in liquid biopsy samples if tumor-derived RNA is detectable.
Early Response Indicator Because the splicing change occurred within 24-48 hours of KRAS inhibitor treatment - before any clinically detectable tumor shrinkage - tracking RPS24 splicing could theoretically allow physicians to confirm drug-target engagement very early in treatment. Patients who show the expected splicing shift might be more likely to benefit from continued therapy.
Distinguishing Responders from Non-Responders If clinical validation confirms that patients whose tumors show strong ex4:3bp isoform upregulation have better treatment outcomes, this metric could identify likely responders to sotorasib or adagrasib at an early timepoint. Conversely, absence of the expected splicing change might indicate primary resistance.
Technical Accessibility Fragment analysis is available in many clinical molecular pathology laboratories and is less expensive than next-generation sequencing. Developing a validated assay around RPS24 isoform quantification could be implementable in routine clinical settings without requiring exotic technology platforms.
Translation to Patient Samples The current findings are entirely from cell lines. The critical next step is demonstrating that RPS24 microexon splicing changes can be detected in RNA extracted from tumor biopsies or circulating tumor cells from patients receiving KRAS inhibitors. Technical challenges include RNA stability in clinical samples and the lower tumor cell fraction compared to pure cell lines.
Liquid Biopsy Integration Tumor-educated platelets, circulating tumor RNA, and exosomal RNA are emerging sources of liquid biopsy material that may carry tumor-specific splicing signatures. If RPS24 isoform ratios can be detected in blood-based samples, this would enable non-invasive longitudinal monitoring without requiring repeat biopsies.
Resistance Mechanism Investigation A key open question is whether RPS24 splicing patterns change again when tumors develop acquired resistance to KRAS inhibitors. Resistance-associated splicing reversion or emergence of novel isoforms could provide mechanistic insight into how cancer cells escape therapy.
Broader Splicing Landscape KRAS inhibition likely affects the splicing of many genes beyond RPS24. Transcriptome-wide splicing analysis in responding versus non-responding tumors could reveal a splicing signature with greater predictive power than any single gene, and might illuminate new mechanisms of KRAS pathway biology.